CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation

Alessandra Dall'Acqua, Maura Sonego, Ilenia Pellizzari, Ilenia Pellarin, Vincenzo Canzonieri, Sara D'Andrea, Sara Benevol, Roberto Sorio, Giorgio Giorda, Daniela Califano, Marina Bagnoli, Loredana Militello, Delia Mezzanzanica, Gennaro Chiappetta, Joshua Armenia, Barbara Belletti, Monica Schiappacassi, Gustavo Baldassarre

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum-treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.

Original languageEnglish
Pages (from-to)1415-1433
Number of pages19
JournalEMBO Molecular Medicine
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2017

Fingerprint

Platinum
Survival
Ovarian epithelial cancer
Heterografts
DNA Damage
Neoplasms
Cell Death
Transcription Factors
Pharmacology
Apoptosis
Cell Line
Therapeutics

Keywords

  • Journal Article

Cite this

CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. / Dall'Acqua, Alessandra; Sonego, Maura; Pellizzari, Ilenia; Pellarin, Ilenia; Canzonieri, Vincenzo; D'Andrea, Sara; Benevol, Sara; Sorio, Roberto; Giorda, Giorgio; Califano, Daniela; Bagnoli, Marina; Militello, Loredana; Mezzanzanica, Delia; Chiappetta, Gennaro; Armenia, Joshua; Belletti, Barbara; Schiappacassi, Monica; Baldassarre, Gustavo.

In: EMBO Molecular Medicine, Vol. 9, No. 10, 10.2017, p. 1415-1433.

Research output: Contribution to journalArticle

Dall'Acqua, Alessandra ; Sonego, Maura ; Pellizzari, Ilenia ; Pellarin, Ilenia ; Canzonieri, Vincenzo ; D'Andrea, Sara ; Benevol, Sara ; Sorio, Roberto ; Giorda, Giorgio ; Califano, Daniela ; Bagnoli, Marina ; Militello, Loredana ; Mezzanzanica, Delia ; Chiappetta, Gennaro ; Armenia, Joshua ; Belletti, Barbara ; Schiappacassi, Monica ; Baldassarre, Gustavo. / CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. In: EMBO Molecular Medicine. 2017 ; Vol. 9, No. 10. pp. 1415-1433.
@article{c71cbd9f87844d37bf213bf1af2cc2bd,
title = "CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation",
abstract = "Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum-treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.",
keywords = "Journal Article",
author = "Alessandra Dall'Acqua and Maura Sonego and Ilenia Pellizzari and Ilenia Pellarin and Vincenzo Canzonieri and Sara D'Andrea and Sara Benevol and Roberto Sorio and Giorgio Giorda and Daniela Califano and Marina Bagnoli and Loredana Militello and Delia Mezzanzanica and Gennaro Chiappetta and Joshua Armenia and Barbara Belletti and Monica Schiappacassi and Gustavo Baldassarre",
note = "{\circledC} 2017 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2017",
month = "10",
doi = "10.15252/emmm.201607012",
language = "English",
volume = "9",
pages = "1415--1433",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation

AU - Dall'Acqua, Alessandra

AU - Sonego, Maura

AU - Pellizzari, Ilenia

AU - Pellarin, Ilenia

AU - Canzonieri, Vincenzo

AU - D'Andrea, Sara

AU - Benevol, Sara

AU - Sorio, Roberto

AU - Giorda, Giorgio

AU - Califano, Daniela

AU - Bagnoli, Marina

AU - Militello, Loredana

AU - Mezzanzanica, Delia

AU - Chiappetta, Gennaro

AU - Armenia, Joshua

AU - Belletti, Barbara

AU - Schiappacassi, Monica

AU - Baldassarre, Gustavo

N1 - © 2017 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2017/10

Y1 - 2017/10

N2 - Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum-treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.

AB - Epithelial ovarian cancer (EOC) is an infrequent but highly lethal disease, almost invariably treated with platinum-based therapies. Improving the response to platinum represents a great challenge, since it could significantly impact on patient survival. Here, we report that silencing or pharmacological inhibition of CDK6 increases EOC cell sensitivity to platinum. We observed that, upon platinum treatment, CDK6 phosphorylated and stabilized the transcription factor FOXO3, eventually inducing ATR transcription. Blockage of this pathway resulted in EOC cell death, due to altered DNA damage response accompanied by increased apoptosis. These observations were recapitulated in EOC cell lines in vitro, in xenografts in vivo, and in primary tumor cells derived from platinum-treated patients. Consistently, high CDK6 and FOXO3 expression levels in primary EOC predict poor patient survival. Our data suggest that CDK6 represents an actionable target that can be exploited to improve platinum efficacy in EOC patients. As CDK4/6 inhibitors are successfully used in cancer patients, our findings can be immediately transferred to the clinic to improve the outcome of EOC patients.

KW - Journal Article

U2 - 10.15252/emmm.201607012

DO - 10.15252/emmm.201607012

M3 - Article

C2 - 28778953

VL - 9

SP - 1415

EP - 1433

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 10

ER -